Rapid Infliximab Infusion in the Pediatric Population.

ABSTRACT:

Objectives

To compare infusion reaction rates between rapid infliximab (REMICADE, Janssen Biotech Inc) infusions and previous standard 2- to 3-hour infusions; additionally, to assess patient satisfaction and reduction in chair time associated with rapid infliximab infusions.

Methods

Pediatric rheumatology and gastroenterology patients receiving maintenance infliximab therapy using a standard 2- to 3-hour titrated infusion had the opportunity to enroll in the non-titrated rapid 1-hour infusion protocol following tolerance of induction dosing at 0, 2, and 6 weeks. Patients were included from December 1, 2017, to March 31, 2018, via retrospective chart review and patient satisfaction surveys.

Results

Data were collected on 55 patients receiving a total of 160 rapid infli

SUBMITTER: Munsel EJ 

PROVIDER: S-EPMC7671021 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature